At Crossfire Oncology we have a deep understanding of kinases that play a pivotal role in many cellular processes, including proliferation, survival, migration, and differentiation.
Based on our proprietary EPriL (Energetically Privileged Ligands) chemistry we have developed a unique platform of kinase inhibitors, degraders, and degrader antibody conjugates (DACs). This allows us to select and develop the most suitable approach for each target kinase to ensure an optimal therapeutic effect.
The Crossfire team has decades of experience in medicinal chemistry and was closely involved in the design of clinically and commercially successful drugs. BAL0891, a potent TTK/PLK1 inhibitor, was fully designed in house and is currently in clinical development.